Liu Wei, Zhu He-Min, Niu Guo-Jun, Shi En-Zhi, Chen Jie, Sun Bo, Chen Wei-Qiang, Zhou Hong-Gang, Yang Cheng
College of Sciences, Tianjin University of Science and Technology, Tianjin 300457, China.
College of Life Sciences, NanKai University, Tianjin 300071, China.
Bioorg Med Chem. 2014 Jan 1;22(1):292-302. doi: 10.1016/j.bmc.2013.11.028. Epub 2013 Nov 21.
The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CL(pro). 3CL(pro) plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL(pro) inhibitors was designed, synthesized, and evaluated by in vitro protease assay using fluorogenic substrate peptide, in which several showed potent inhibition against the 3CL(pro). Structure-activity relationship was analyzed, and possible binding interaction modes were proposed by molecular docking studies. Among all compounds, 8k₁ showed most potent inhibitory activity against 3CL(pro) (IC₅₀=1.04 μM). These results indicated that these inhibitors could be potentially developed into anti-SARS drugs.
严重急性呼吸综合征(SARS)是由SARS冠状病毒引起的一种严重威胁生命且致死率极高的呼吸系统疾病。SARS冠状病毒含有一种类似于主要微小核糖核酸病毒蛋白酶3CL(pro)的类胰凝乳蛋白酶样主要蛋白酶。3CL(pro)在病毒复制周期中起关键作用,是开发SARS抑制剂的潜在靶点。设计、合成了一系列可能作为SARS冠状病毒3CL(pro)抑制剂的异吲哚酮衍生物,并通过使用荧光底物肽的体外蛋白酶测定法进行评估,其中几种对3CL(pro)表现出强效抑制作用。分析了构效关系,并通过分子对接研究提出了可能的结合相互作用模式。在所有化合物中,8k₁对3CL(pro)表现出最有效的抑制活性(IC₅₀ = 1.04 μM)。这些结果表明,这些抑制剂有可能被开发成抗SARS药物。